Auto-Injector Market Research Report- Forecast till 2027

Auto-Injector Market Research Report: By Product Type (Disposable, Reusable), Application (Anaphylaxis, Multiple Sclerosis, Diabetes, Allergies, Rheumatoid Arthritis, Others), Distribution Channel (Online Retailer, Pharmacy, Others), End-User (Home Care Settings, Hospitals & Clinics, Ambulatory Surgical Centers), and Region (Americas, Europe, Asia-Pacific, and Middle East and Africa)- Forecast till 2027

ID: MRFR/MED/1514-HCR | February 2021 | Region: Global | 85 pages

Auto-Injector Market

The auto-injector market size is projected to grow by 22% and market value will reach 125.32 million in forecast period 2020-2027.

Segmentation

By Product Type Disposable Reusable
By Application Anaphylaxis Multiple Sclerosis Diabetes Allergies Rheumatoid Arthritis
By Distribution Channel Online Retailer Pharmacy
By End-User Home Care Settings Hospitals & Clinics Ambulatory Surgical Centers

Key Players

  • Merck KGaA
  • AbbVie Inc
  • Antares Pharma
  • Eli Lilly and Company
  • Teva Pharmaceutical
  • Amgen
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Becton Dickinson and Company

Drivers

  • The pharma companies are raising the launch of advanced auto-injectors
  • The growth of the geriatric population
  • Increased adoption and use of auto-injectors
Speak to Analyst Request a Free Sample

Auto-Injector Market Overview 


The auto-injector market size is projected to grow by 22% in the forecast period. The auto-injector is a type of syringe that has pre-dosage drugs. It triggers the right amount of drugs in the syringe. Injecting a measured amount of drugs into a sliding motion is an exceptional feature of this device. Auto-injectors are useful for personal purposes. It is an exceptional injector for self-administration. Also, it is beneficial for epinephrine and migraine conditions. For medical and urgent treatments the usage of an auto-injector is essential. There are plenty of benefits of auto-injectors.


 Few advantages of the auto-injectors are it is a suitable syringe for individuals with phobia disorders. It lessens the accidents of the needle getting stuck into the body. Also, it is useful for proper dosage quantity and injection effectiveness. The auto-injectors are receiving plenty of awareness in recent years. Today, due to lockdown many are rapidly adopting auto-injectors.


Many patients and their families learn self-administration. It saves effort and time of visiting hospitals for very injections. With the auto-injectors, arthritis patients, multiple sclerosis and other chronic disease patients can benefits. Patients with chronic illness require everyday injections. With the help of auto-injectors, the accuracy and effectiveness of the medicine are high. In the forecast year, the auto-injector market value will reach 125.32 million. 


Covid analysis 


The outbreak of covid 19 has lead to a global health crisis. The health sector is more during this period. Demand for non-essential medical services has reduced massively. The number of patients visiting hospitals for treatment other than covid 19 reduced to 40%. Patients are delaying the treatment and injections required for chronic illness. It has a declining impact on the auto-injector market.


There is a slowdown in the launch of treatments required for chronic illness. Due to these factors, the auto injector’s market growth is slowing down. However, the pharmaceutical company market is key end-users for auto-injectors. It is accelerating the demand for auto inject in the current year. The development of pharmaceutical companies is creating a positive impact on the auto-injector market. Overall the auto-injector market analysis trend remains positive during this period. 


Market dynamics 



  • Crucial market drivers 


The rise of anaphylaxis is severe in many regions. It is a dangerous food reaction that causes deadly allergies. One out of 1000 people in the population has an anaphylaxis reaction. Further, the patients suffering from this disorder is high during anesthesia. Epinephrine is the primary treatment available for anaphylaxis. The pharmaceutical companies are raising their production of auto-injectors that contain epinephrine. 


The pharma companies are raising the launch of advanced auto-injectors. The need for injector caps, injection dosage and audible click detection is improving in the new models. The availability of these injectors is growing during the forecast period. Earlier, the auto injector’s cases were fewer. However, in many patients, it is effortlessly available for home use. Increased adoption and use of auto-injectors will grow the auto-injector market size. The growth of the geriatric population is another demand driving factor of auto-injector market. auto-injector market profitability will increase due to these factors. 



  • Market growth opportunities 


Due to the covid 19 pandemic, new protocols are created for a patient visiting the hospitals. During non-emergency cases, the healthcare industry is taking preventive measures. These protocols help to stop the spread of the covid virus. The need to limit the number of patients visiting the hospital for non-emergency purposes is rising growth opportunities. The presence of home injection is highly prevalent among many patients.


Especially, the patient with chronic illnesses finds these auto-injectors highly beneficial. Also, the increasing awareness about this injector is another factor leading to growth opportunities. Rheumatoid arthritis is another crucial reason for the growth of the auto-injector market. Patients with a severe allergy do not need to delay the treatment. With the help of auto-injectors, quick treatment is possible. In the covid 19, the application of auto-injectors has expanded. In the upcoming years, more patients and end-users will have a high demand for auto-injectors. The auto-injector market expansion rate for the market is immense in the forecast year. All these will lead exceptional auto-injector market growth opportunities. 



  • The market restraints 


The traditional injections are invasive and painful. It is leading to more demand for clinical drugs, oral, nasal and other modes of treatment. The oral route of medicines is preferred by half the population. The ease of use, convenience and cost are some of the benefits of clinical drugs. It is a safe and acceptable form of medication for many. Today, digital pharmacy services are expanding rapidly. It is a reliable form of delivering drugs to patients.


The growth of drug delivery market restraints the growth of the auto-injector market. The anxiety about needles is less due to these drugs. There is a decline in injection treatment in many regions. It is changing the customer preference towards the painless drug market. From children to chronic illness patients prefer fewer pain meds of treatment. The anxiety of needles is the key factor restraining auto-injector market growth. 



  • The market challenges 


There are different types of chronic illnesses requiring daily injections. However, the versatility of the illness creates different requirements for auto-injectors. The injection capacity, dosage, length and thickness require being different for each of the medications. These factors lead to different types of auto-injectors.


 It is a challenging aspect of the market. The non-availability of proper auto-injectors and lack of product versatility can have a declining effect on the auto-injector market. The OEM lacks the knowledge of manufacturing multiple drugs. The key players are taking efforts to eradicate these market challenges. With more research, the market is trying to cope with this challenge. 



  • Cumulative growth analysis 


The overall growth rate of the auto-injector market is stable in the forecast period. There are few factors that continually propel the demand of the market. The rising urgency of injection in allergic cases is stirring the demand for the auto-injector market. Due to chronic illness, the adoption of auto-injectors is tremendous in many regions. The awareness about self-administration is leaving to more profits for the market.


Further, the key players are increasing the availability of these auto-injectors. Due to convenience and ease of access many users prefer auto-injectors. The anxiety about the injection and growth of digital pharmacy services is a retaining factor of auto-injector market. Overall the growth trend of the auto-injector market is promising for the forecast period. 



  • The value chain analysis 


The Asia Pacific market is expected to outgrow other regional players in the forecast period. The demand for auto-injectors is high in this region. The immense growth of diabetes patients is raising the demand for the product. Further, the health care infrastructure is developing at an exponential pace.


It leads to more manufacture of auto-injectors. Home care and self-administration in chronic illnesses is surging in this region. For non-urgent cases, many patients and their families learn to use auto injectors. The presence of top auto-injector market companies is advantageous for market growth. There is constant development and high demand for auto-injectors in Asia pacific region. 


Segment overview 


By therapy 



  • Anaphylaxis

  • Rheumatoid Arthritis

  • Diabetes

  • Multiple Sclerosis


By type 



  • Reusable auto-injectors 

  • Disposable auto-injectors 


by administration 



  • Intramuscular 

  • Subcutaneous 


By end-user 



  • Ambulatory care 

  • Home care 

  • Hospital care 


By geography 



  • Middle East 

  • Asia pacific 

  • Europe 

  • North America 


Competitive landscape 


The competition in the auto-injector market is rising in the forecast period. The key players will lead to more research and innovation. Market acquisitions, expansion and partnerships are part of the competitive landscape. New product launches and segment expansions are key strategies of the market players. 


Regional analysis 


The auto-injector market is fragmented into Asia Pacific, Europe, Middle East and North America. The Asia Pacific will hold the maximum auto-injector market share. The investment for the health industry is rising in Asia pacific. It will fuel the production of auto-injectors in Asia pacific.


Through partnerships with local pharmacies, the region is expanding its market. North America is the next region with the highest market demand. The adoption of auto-injectors is rapid in this region. Also, the high spending power of customers will lead to more growth of auto-injectors. It is a market with the highest profitability rate in the forecast period. 


The key players of the auto-injector market are 



  1. Merck KGaA

  2. AbbVie Inc

  3. Antares Pharma

  4. Eli Lilly and Company

  5. Teva Pharmaceutical 

  6. Amgen 

  7. Johnson & Johnson

  8. GlaxoSmithKline plc 

  9. Becton, Dickinson and Company


Recent developments 



  1. The key players of the market are signing new projects for the production of auto-injectors in the middle east.  



  1. The key players are introducing auto-injection delivery systems in many regions. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2025: USD 125.32 million
  CAGR   2019-2025: 22.0%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units    Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   product type, application, distribution channel, end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG, Haselmeier, Novartis AG, Owen Mumford Ltd, Becton, Dickinson and Company, AbbVie Inc., Johnson & Johnson, Amgen Inc., Teva Pharmaceuticals USA, Biogen, Eli Lilly and Company, Mylan NV, Ypsomed AG, Merck KGaA, AstraZeneca, and Kaleo, Inc.
  Key Market Opportunities   availability of alternatives such as continuous glucose monitoring devices
  Key Market Drivers

  • increasing availability of generic auto-injectors
  • growing geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    auto-injector market is projected grow at approximately 22% CAGR during the assessment period (2019-2025).

    The valuation of the auto-injector market had reached USD 37.44 MN in 2018.

    The valuation of the auto-injector market is estimated to increase to USD 125.32 MN by the end of 2025.

    North America holds the largest share in the global auto-injector market, followed by Europe and the Asia Pacific, respectively.

    Haselmeier, Bayer AG, Novartis AG, Becton, Dickinson and Company, Owen Mumford Ltd, AbbVie Inc., Amgen Inc., Johnson & Johnson, Teva Pharmaceuticals USA, Eli Lilly and Company, Biogen, Mylan NV, Merck KGaA, Ypsomed AG, Kaleo, Inc., and AstraZeneca, are some of the major players operating in the auto-injector market.